The Helsinki-based company said it will use the funds to support further development of its AI-based digital pathology platform.

The firm touted a new clinical chemistry and immunoassay instrument and brain health assays in its diagnostics business during a call with investors on Friday morning.

A panel discussion at the Association for Diagnostics & Laboratory Medicine this week tackled questions around coding, reimbursement, and regulation of AI-based tests.

The firm increased its full-year guidance to a new range of $1.34 billion to 1.36 billion from a previous range of $1.30 billion to $1.32 billion.

The company reported Q2 2026 revenue of $3.73 billion compared to $3.53 billion in the year-ago period, beating Wall Street's consensus estimate of $3.71 billion.

The platform combines machine learning and sample preparation techniques with the firm's proprietary Raman spectral databases.

The partners are also working together to validate the company's molecular testing technologies in various settings.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

NEW YORK – As the liquid biopsy space has exploded in recent years, clinical laboratories are struggling to find sufficient staff to oversee and run these assays. Staffing is a problem for the ...

The firm revised its revenue guidance for full-year 2026 to a range of $802 million to $806 million, and its net loss for the year to a range of $42 million to $34 million.